RU2414246C2 - Infusion and transfusion therapeutic device - Google Patents

Abstract

FIELD: medicine.

SUBSTANCE: invention refers to medicine, aims at executing infusion and transfusion procedures with using activated therapeutic solutions and can be used in introduction of bulk of a fluid - normal saline, blood, glucose, etc. with drug substances added. An infusion and transfusion therapeutic device comprises a dropper consisting of a sealed package of a therapeutic solution, a medicine tube, a needle connecting the medicine tube and sealed package, an injection needle and an electrolytic cell. An activator fluid tank comprise an embedded hollow cup made of a dielectric material and holed along the full length. The electrolytic cell represents an undivided activator and is placed between the sealed package of the therapeutic solution and injection needle. The medicine tube is placed inside the electrolytic cell along its full length and wound round the hollow cup.

EFFECT: enabled activation of the therapeutic solutions, including blood and blood substitutes, immediately during an infusion or transfusion therapy provided maintaining target omnipresent electrical potential of the activator fluid (820+100 mV).

1 dwg, 8 ex

Description

The invention relates to medicine and relates to the implementation of infusion and transfusion procedures using activated therapeutic solutions. The invention can be used with the introduction of large quantities of liquid - saline, blood, glucose, etc. with the addition of medicinal substances.

Infusion-transfusion therapy is one of the most important components of intensive care for most critical conditions. For this purpose, over a fairly long period of time, a wide range of therapeutic solutions are used in clinical practice. Conducting infusion-transfusion therapy is carried out to restore the volume and composition of the extracellular and intracellular water space of the body using parenteral administration of fluid, including to restore the proper content of chemical elements (calcium, potassium, chlorine, etc.) necessary for normal life, as well as to remove toxic substances and stimulate or, conversely, reduce the intensity of the organ. Indications for infusion therapy are a lack of fluid volume that occurs with the loss of water and electrolytes, plasma and blood; changes in osmolarity, deficiency or excess of individual components of the plasma volume. Infusion therapy is also used when it is impossible to use the enteric pathway for the absorption of water and nutrients.

The most important parameter of a liquid, from the point of view of modern medicine, is its “charge” - the redox potential (ORP), which should be negative, since human cells have a negative ORP (-70 mV). Diseases occur when negative cell potential (AFP) drops below normal. Activated in one way or another, water has a negative ORP, a microcluster structure, is easily absorbed by the body, and replenishes negative blood cells and energy lost during illness.

In order to stimulate general immunity, including to enhance the activity of blood cells, therapeutic solutions introduced into the body, including during infusion therapy, are activated, which allows the blood to be enriched with trace elements with a change in the structure and properties of blood, but without changing its chemical composition . The phenomenon of effective treatment of a wide variety of diseases using biologically active liquids is well-known and confirmed by practice (Shironosov V.G. Physical fundamentals of resonant activation of water, p.220-221, 1st International Symposium "Electrochemical Activation in Medicine, Agriculture, Industry", collection of reports - M .: VNIIMT AO NPO Ekran, 1997. - P.248 In particular, positive clinical experience has been gained when using contactlessly activated physiological saline (DF) for droppers using the Kiselev method using a laser (Kisele in B.I. Adaptive treatment method (an artificial source of a biofield in medicine). St. Petersburg: "Complex", issue 1. 1997, 9 pp.).

The effect of non-contact activation of liquids in non-diaphragm electrolysis was demonstrated by the operation of a device developed, theoretically justified in 1984, and experimentally confirmed by Shironosov V.G. et al. in 1999: non-contact activated infusion solutions (BAIR) were used to prevent postoperative pancreatitis in cancer patients. As a result, the complication rate of postoperative pancreatitis decreased from 71% in the control group to 26% in the group using BAIR. (Shironosov V.G., Napolskikh V.M., Sorokin E.P., Kubashev A.P. Application of contactlessly activated infusion solutions for the prevention of postoperative pancreatitis in cancer patients. Abstracts of the IV International Congress "Weak and superweak fields and radiation in biology and medicine ", July 03-07, 2006. St. Petersburg. P.218).

The phenomenon of effective treatment of various diseases using contactless activated fluids (BAL) is explained as follows. The cells themselves in the body are a kind of miniature reactors for electrochemical activation (ECA), and the same applies to non-contact activated fluids in the body. The resulting high-energy systems of oscillating dipoles (SOD) form a synchronous framework, which provides the main energy and immune status of the body. Accordingly, treatment with BAJ helps restore the energy of SOD at certain frequencies (Shironosov V.G. The phenomenon of living water and its simple explanation. XIII International Symposium "International Year of Water - 2003", Abstracts. Section: Water, as a source of life. Austria, 29 March - April 5, 2003, pp. 246-249). Studies have also shown that under the influence of non-contact activation, a change in the metabolism in red blood cells occurs (Kazankin D.S. et al. The non-contact effect of activated aqueous solutions on the hemolysis of red blood cells. Collection of abstracts VNKSF-13, Rostov-on-Don - Taganrog, 20-26 April 2007. S. 465-466).

With non-contact activation of infusion solutions, the system goes into a nonequilibrium thermodynamic state with higher energy. In this case, stable nonlinear resonance systems arise from oscillating "dipoles" (two or more) - water, OH. In statics, such systems from dipoles are unstable (collapse effect), but in dynamics during resonance the effect of dynamic stabilization of unstable states is manifested. The systems obtained from activation of high-quality "molecular resonators" with a quality factor of ~ 10-13 or more are responsible for the "unusual" properties of contactlessly activated liquids (Dubrovskaya O.A., Mulakhmetov R.F., Shironosov V.G. The phenomenon of contactless activation from microhydrin and in chemical reactions. Collection of abstracts of VNKSF-8, Yekaterinburg, 2002. - p.597-599).

A decrease in the AFP of tissues and organs, as well as liquid biological media, is accompanied by radioprotective action, regardless of how the decrease in AFP is caused (hypoxia, the introduction of antioxidants or the production of endogenous radioprotectors). At the same time, the body neutralizes oxidized products by creating the conditions for their interaction with an excess of reduced molecules. As a result, the risk of irreversible peroxide damage to the biosubstrate is reduced. (B.I. Leonov, V.I. Prilutsky, V.M. Bakhir. Physical and chemical aspects of the biological action of electrochemically activated water. M., 1999, p. 39-41).

In oncology, against the background of radiation therapy, the blood of patients is activated by intravenous laser irradiation, when a marked decrease in necrobiotic processes is noted on the 5-7th day after the operation, there is no edema and leukocyte tissue infiltration, vascularization improves, and the number of newly formed vessels significantly increases. The nature of the anti-inflammatory effect of intravenous laser irradiation is confirmed by changes in peripheral blood. Leukocytosis, ESR decreases, the proportion of segmented neutrophils decreases. The number of lymphocytes significantly increases by the end of the first week of the postoperative period. The use of intravenous laser irradiation of blood increases the absolute number of lymphocytes in peripheral blood, activates T-lymphocytes and stimulates their rosette-forming activity. The use of this method against the background of radiation therapy for cancer patients has a beneficial effect on the immune status of patients.

A known method of preparing blood for transfusion by exposure to blood with electromagnetic radiation (application for US Pat. RF No. 2001127417, MKI A61M 1/36 "Method of exposure to electromagnetic radiation", publ. 2000.06.27).

A known method of treating blood for subsequent transfusion with therapeutic purposes. The method consists in additional processing of red blood cells by additional irradiation of blood during transfusion in order to increase the efficiency of restoring the functional properties of blood (US Pat. RF No. 2133613, MKI A61K 35/14, A01N 1/02 "Method of pre-transfusion processing of preserved red blood cells", publ. 1999.07 .27). In order to confirm the positive effects of activation, we studied the water, physiological saline, and venous blood of humans (Konovalova N.A., Menshikova S.G., Shironosov V.G. Registration of the phenomenon of non-contact activation of liquids. Department of Biophysics, Udmurt State University, Izhevsk , Collection of abstracts of VNKSF-8, Yekaterinburg, 2002. - p.590-592).

A device for electrochemical processing of liquid according to US Pat. at PM No. 70655 (02/10/2008), including a glass of dielectric material with perforated side walls, inside of which an electrode is located.

The prototype is a device for preparing blood for transfusion using non-contact blood activation in a non-diaphragm electrolyzer, for example, in an Espero electrolyzer. Hermetic thin-walled polyethylene containers were filled with blood with a volume of V = 50 ml and placed in the cell for 30 minutes. The cell with a coaxial anode and cathode was filled with tap water with a volume of V = 1.8 L, with the addition of sodium chloride in an amount of 9 g / L. After activation, blood parameters were measured. (Prilutsky V.I., Bakhir V.M. Electrochemically activated water: Anomalous properties, mechanism of biological action. - M .; VNIIIMT AO NPO Ekran. 1997). This device for contactless activation is intended for the prevention and treatment of various diseases in order to stimulate general immunity, including to enhance the activity of blood cells. Activation of therapeutic solutions allows the blood to be enriched with trace elements ions, leads to activation, with a change in its structure and properties, but without changing the chemical composition of the blood.

However, this device for preparing for transfusion or infusion of therapeutic solutions, including blood and blood substitutes, like all known devices is limited in that:

1. The activation of therapeutic solutions, including blood and blood substitutes directly during the infusion or transfusion therapy is impossible;

2. After removing the containers with treatment solutions from the activating fluid, relaxation of the ORP values of the treatment solutions begins, which decreases significantly after 30-40 minutes.

The objective of the invention is the creation of a device that enables the activation of therapeutic solutions, including blood and blood substitutes, directly during infusion or transfusion therapy, provided that the electric potential of the activating fluid is constantly maintained at a given level (820 ± 100 mV).

The problem is solved in that in a device for conducting infusion and transfusion therapy, including a dropper, consisting of a sealed bag with a treatment solution, a medical tube, a needle connecting the medical tube to a sealed bag, an injection needle, an electrolyzer-free diaphragm activator is placed between the sealed bag with treatment solution and injection needle, and the middle part of the medical tube along its length is placed inside the cell. A hollow cup of dielectric material with holes along the entire length of the wall of the cup according to US Pat. at PM No. 70655, and the medical tube placed inside the cell is wound along a helical line around the hollow glass, for which helical grooves are made on the outer wall of the glass along the entire height to tightly fit the tube to the walls of the glass.

The drawing shows a General view of the device for infusion and transfusion therapy.

The device includes a dropper 1, consisting of a sealed bag (plastic bag) 2 with a treatment solution or blood, a medical tube 3, a needle 4, a tap 5, and an electrolyzer in the form of a diaphragmless activator 6 with anode 7 and cathode 8, anode chamber 9, placed in capacity 10 with activating liquid.

The hollow glass 11, covering the cathode 8, is installed in a container 10 with an activating liquid. A sealed bag 2 with a treatment solution or blood through a needle 4 is connected to a medical tube 3 of a dropper 1, through which a treatment solution or blood flows to the patient through an injection needle 12. A hollow glass 11 installed in a container 10 with an activating liquid is made of dielectric material, and in the walls of the glass 11 holes are made to fill the entire volume of the tank 10 with activating liquid. On the outer wall of the glass 11 over the entire height, it is recommended to make screw grooves to accommodate the medical tube 3. The length of the tube 3 in its part located inside the cell is at least 1.5 m.

According to the claimed technical solution in the device for infusions and transfusions, the level of AFP in the activating fluid is brought to values within 820 ± 100 mV (depending on the type of activated solution (fluid) administered to the patient). This value is controlled by known means (for example, ORP-metry) and is maintained throughout the entire infusion (transfusion) procedure. Due to the fact that the target ORP values are monitored and maintained within specified limits during the infusion (transfusion) procedure, we obtain the desired ORP values of the activated solutions.

At the same time, our experience of many years of using the claimed technology confirms that with the formation of an electric circuit "liquid in the tube - needle - body", parasitic currents that adversely affect the patient do not occur, because the OPV value of the activated liquid at the injection stage remains almost unchanged, and if it changes, it is very insignificant, as shown in comparative examples with the electrolyzer turned on and off.

The advantage of the claimed device and activation technology is achieved by placing the electrolyzer between an airtight bag with a therapeutic solution and an injection needle, i.e. there is no need to remove the container with the activated solution from the activating liquid. Thus, the advantage compared with the prototype lies in the fact that the ORP values of the treatment solution or blood practically remain unchanged: the treatment solution after leaving the dropper = -250 mV ± 3 mV, at the end of the infusion = -230 mV ± 3 mV; blood after activation = -340 mV ± 3 mV, after transfusion (infusion) = -320 mV ± 3 mV (table 1). In the solution of the prototype, after removing the container with the activated solution from the activating liquid, relaxation of the ORP of the solutions begins, which decreases after 30-40 minutes.

The device operates as follows. To prepare the activating liquid, the container 10 is filled with distilled water, baking soda is added at the rate of 1 tbsp. spoon per 1 liter of water. Diaphragmless activator 6 with electrodes 7 and 8, placed in the capacitance 10, is connected to the network and activation of the liquid in the capacitor 10 is started. Activation is carried out up to the ORP value = -800 ± 100 mV. The faucet 5 is opened and the treatment solution or blood is passed through the medical tube 3 along its entire length, up to the injection needle 12. Infusion of the treatment solution or blood transfusion is started. In this case, the treatment solution or blood is administered to the patient at a speed of not more than 1 drop per second. The attached to the description of table 1 shows the comparative data of the device of the prototype and the claimed device in relation to the preservation of the specified values of the ORP of therapeutic solutions both during infusion (transfusion) and at the end of the process of introducing solutions, blood or blood substitutes to the patient.

Table 1 No. p / p Prototype Patent Device Preservation of preset values of ORP solutions during infusion (transfusion) Claimed device Preservation of preset values of ORP solutions during infusion (transfusion) one. The preliminary activation of solutions in plastic bags is carried out (before infusion, transfusion) Values of the ORP of solutions: at the beginning of the procedure, ORP = -258 mV, at the end of the procedure, after 30 minutes, ORP = -15 mV The activation of treatment solutions occurs during infusion (transfusion) The values of the ORP of therapeutic solutions after activation: after leaving the dropper ORP = -250 mV; at the end of the infusion (transfusion) ORP = -230 mV
Blood AFP values after AFP activation = -340 mV at the end of AFP transfusion = -320 mV

The technical result in terms of increasing the effectiveness of the functional properties of therapeutic solutions is achieved by bringing the ORP values of the activated solutions to the necessary indicators: the required indicators are not the absolute indicators of the ORP of the solutions, but the shift of the ORP to the negative side during non-contact activation of the solutions, which during non-contact activation acquire reductive radioprotective properties, which increases their effectiveness. At the same time, the body neutralizes oxidized products by creating the conditions for their interaction with an excess of reduced molecules.

Non-contact activation of blood and its components, which changes the structure and properties of blood without changing its chemical composition, opens up new prospects for the practical use of this effect in medicine - for the prevention and treatment of various diseases, for blood incubators.

To confirm the theoretical justification for increasing the effectiveness of therapeutic solutions during their activation, the results of our measurements of AFP (before and after activation) of some infusion solutions that are most often used in clinical practice are given (table 2).

table 2 A drug ORP before activation, mV AFP after activation, mV Disol -fifty 225 Glucose 5% -380 210 Hemoches -98 -208 Glucose 10% -345 -185 Acesol -70 -175 Reopoliglyukin -129 -148 Ringer's solution -250 -216 Saline -320 -210 Metranidazole -151 -170 Blood plasma 6 -325 Erythrocyte mass -70 -435 Aminovenosis 52 -420

The table shows that the AFP of most infusion solutions initially has a positive value (the exception is only some drugs for parenteral nutrition, including amino acids).

EXAMPLES

EXAMPLE 1.1: Prepared a system consisting of Ringer's solution (250 ml) in a sterile plastic bag. An activating liquid was preliminarily prepared, for which the container was filled with distilled water. There they added baking soda at the rate of 1 tbsp. spoon per 1 liter of water. An activator with electrodes was placed in a container with an activating liquid and connected to the network. Activation was carried out for 30 minutes until the ORP value was not lower than = 820 ± -100 mV. Then they took out the bag, connected a standard dropper to it and began to drip at a rate of 1 drop per second.

Result: at the beginning of the procedure, the ORP of the solution = -258 mV, at the end of the procedure after 30 minutes, the ORP of the solution = -15 mV.

EXAMPLE: 1.2: Prepared a system consisting of Ringer's solution (250 ml), and a dropper with an additional extension (1.5 m). An activating solution was prepared by analogy with example 1.1. An extension cord 1.5 m long was placed on a hollow glass along its grooves. A hollow beaker was placed in a container with an activating liquid. The solution was contactlessly activated for 10 minutes. Then they opened faucet 5 and began to drip the solution into the container at a speed of 1 drop in 1 sec. The ORP of the solution was measured at the beginning of the procedure and at the end of the procedure, after 30 minutes. Result: ORP at the beginning of the procedure = -250 mV. ORP at the end of the procedure = -230 mV.

EXAMPLE: 1.3. Prepared a system consisting of Ringer's solution in an amount of 250 ml, in a sterile plastic bag. The preparation of the activating fluid was carried out according to example 1.1. Then a plastic bag with a solution was placed in a container with an activating liquid with an ORP = -820 mV and activated for 30 minutes. Then the package was taken out, a standard dropper and an additional extension of -1.5 m were connected to it. The latter was placed in a container 10 with an activating liquid. Then they opened faucet 5 and began to drip the solution into the container at a speed of 1 drop in 1 sec. The ORP of the solution was measured at the beginning of the procedure and at the end of the procedure. Result: ORP at the beginning of the procedure = -270 mV. ORP at the end of the procedure = -295 mV.

Thus, studies have shown that with the non-contact activation of the Ringer solution according to the prototype method (example 1.1), there is a significant relaxation of the ORP of the solution during the infusion. With the proposed method (examples 1.2, 1.3), the relaxation of the ORP of the solution is practically absent or there is an increase in its performance.

Our studies have proved that under the influence of contactlessly activated infusion solutions there is a significant shift in the ORP of the solution in the negative direction, i.e. the restorative properties of blood are strengthened, which confirms an increase in the effectiveness of the functional properties of therapeutic solutions after non-contact electrochemical activation. To confirm this fact, we give comparative experimental results using the following examples:

EXAMPLE 2.1: A patient was infused with an inactive 5% glucose solution (250 ml). ORP = + 380 mV. In this case, the dropper was prepared in the generally accepted standard way. Before the infusion, a needle was inserted into the peripheral vein and 5 ml of blood was drawn into the syringe. The syringe was removed and a glucose solution was attached to the needle. After taking the blood, her AFP was measured. At the end of the infusion of the glucose solution from the ulnar vein of the other hand, 5 ml of blood was drawn into the syringe and AFP was measured again.

Result: ORP of blood before infusion (-40 mV), ORP of blood after infusion (-36 mV).

EXAMPLE 2.2: A patient was infused with a contactlessly activated 5% glucose solution (250 ml) with an ORP of -210 mV. To prepare the activating liquid, the container 10 (see the drawing) was filled with distilled water, baking soda was added at the rate of 1 tbsp. spoon per 1 liter of water. Diaphragmless activator 6 with electrodes 7 and 8 was placed in a capacitance 10, connected to the network and the activation of a liquid in a capacitor 10 was started. Activation was carried out to an ORP value of -800 ± 100 mV. They opened the faucet 5 and passed the treatment solution through the medical tube 3 along its entire length, up to the injection needle 12. Prior to the infusion, a needle 12 was inserted into the peripheral vein and 5 ml of blood was drawn into the syringe. The syringe was removed and a glucose solution was attached to the needle. Immediately after taking the blood, her AFP was measured. They started the infusion of the treatment solution. In this case, the treatment solution was administered to the patient at a rate of not more than 1 drop per second. At the end of the infusion of glucose solution from the ulnar vein of the other hand, 5 ml of blood was taken into the syringe and AFP was measured.

Result: ORP of blood before infusion (-52 mV), ORP of blood after infusion (-155 mV).

EXAMPLE 3.1: The patient was infused with an aminovenosis solution (250 ml) with an AFP of -52 mV. A dropper was prepared in a standard way. Before the infusion, a needle was inserted into the peripheral vein and 5 ml of blood was drawn into the syringe. The syringe was removed and a system with an aminovenosis solution was attached to the needle. Immediately after taking the blood, the AFP was measured. After the end of the infusion, 5 ml of blood was taken from the ulnar vein of the other hand into the syringe and AFP was measured.

Result: ORP of blood before infusion (-36 mV), ORP of blood after infusion (-38 mV).

EXAMPLE 3.2: A patient was infused with a contactlessly activated aminovenosis solution (250 ml) with an AFP of -420 mV. In this case, the solution was activated according to example 1.1. Before the infusion, a needle was inserted into the peripheral vein and 5 ml of blood was drawn into the syringe. The syringe was removed and a system with an activated aminovenosis solution was attached to the needle. Immediately after taking the blood, her AFP was measured. After the end of the infusion from the ulnar vein of the other hand, 5 ml of blood was drawn into the syringe and AFP was measured.

Result: ORP of blood before infusion (-48 mV), ORP of blood after infusion (-252 mV).

Thus, studies have shown that non-activated solutions with both positive AFP (5% glucose solution) and negative AFP (aminovenosis solution) do not affect blood AFP.

To test the effectiveness of contactless activation of infusion solutions with and without the electrolyzer, the following experiments were performed:

EXAMPLE 4.1. A system was prepared consisting of Ringer's solution (250 ml) and a dropper with an additional extension cord (1.5 m). ORP of Ringer's solution before activation = +250 mV. An activating liquid was prepared and Ringer's solution was contactlessly activated according to Example 1.1. The tube 3 was activated in the activating liquid for 10 minutes, after which, when the electrolyzer was turned on, the faucet 5 was opened and the solution began to drip into the container. The ORP of the solution was measured at the beginning of the procedure and at the end of the procedure.

Result: ORP at the beginning of the procedure = -250 mV. ORP at the end of the procedure = -230 mV.

EXAMPLE 4.2: A system was prepared consisting of Ringer's solution (250 ml) and a dropper with an additional extension (1.5 m). An activating liquid was prepared and the solution contactlessly activated according to Example 1.1. Upon reaching the ORP value of the activated liquid = -820 mV, the cell was turned off. Tube 3 was activated in an activating fluid for 10 minutes. They opened the faucet 5 and began to drip the solution into the container. The ORP of the solution was measured at the beginning of the procedure and at the end of the procedure. Result: ORP at the beginning of the procedure = -235 mV. ORP at the end of the procedure = -210 mV.

Thus, the ORP values of solutions with the electrolyzer turned on and off are not significantly changed.

The claimed activation method has been used by us in clinical practice since 2002. Clinical trials of the method were carried out in clinics in Los Angeles, Sant Diego, Dallas, Singapore from 2007 to 2009. Patients with various pathologies were treated: cancer grade 3.4, Parkinson's disease, autism, allergy, stroke, eczema, bronchial asthma , hypertension, etc. In all cases, a positive effect was obtained (the results of the studies are published on the website www.umedt.com). We give one example of clinical practice.

Patient I., 82 years old, diagnosis: condition after a repeated stroke. Objectively: the patient is inhibited, does not talk, does not answer questions, does not move, does not respond to relatives. He can neither eat nor drink on his own. The patient spent 20 days in a clinic in Los Angeles. He underwent all the necessary therapy for this pathology, including infusion therapy, vasodilator, vitamins, etc. The condition is unchanged. The patient was admitted to the clinic of alternative medicine, where he was given droppers with contactlessly activated Ringer's solutions - 250 ml + vitamin C + vitamin B complex. (ORP = -420 mV). After 5 droppers, the patient began to speak, recognizes relatives. He began to eat and drink on his own. He began to move with his wand and with the support of others.

Claims (1)

A device for conducting infusion and transfusion therapy, including a dropper, consisting of a sealed bag with a treatment solution, a medical tube, a needle connecting the medical tube to a sealed bag, an injection needle, and a hollow glass of dielectric material with holes the entire length of the glass, characterized in that the electrolyzer in the form of a plateless activator is placed between the sealed bag with the treatment solution and the injection needle, and the medical Single tube over its entire length is placed in the cell and is wound around a hollow glass.

Images